Poolbeg Pharma CEO participating in key conferences in March and April 2025

Poolbeg Pharma

Poolbeg Pharma Plc (LON:POLB), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, has announced that CEO, Jeremy Skillington, will be participating in the following leading industry conferences in March and April 2025:

Master Investor Show – Business Design Centre, London, UK

Presentation details: 29 March, Showcase Stage (Ground Floor), 1.00pm – 1.10pm

Poolbeg Pharma will be located at Booth M30.

BioTrinity – Convene, 133 Houndsditch, London, UK

Presentation details: 2 April, Science Spotlight 8 – Rare Disease, 9.30am – 11am

Poolbeg Pharma’s presentation will focus on its drug candidate POLB 001, an oral preventative therapy for cancer immunotherapy-induced CRS.

LSX World Congress – Business Design Centre, London, UK

Panel title: “Thriving Amidst Turbulence: Building Resilience in Life Sciences”

Panel date & time: 30 April, 2pm

If you would like to meet the Poolbeg Pharma team at any of the above events, please contact us at [email protected].

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Poolbeg Pharma raises £4.7m through Placing and Subscription

Poolbeg Pharma has successfully raised £4.715 million to fund innovative clinical trials, including POLB 001 and an oral GLP-1 programme, addressing critical medical needs.

Poolbeg Pharma launches £4.1m fundraising

Poolbeg Pharma plc (LON:POLB) announces a conditional fundraising aimed at raising £4.1 million to drive innovative pharmaceutical developments and address unmet medical needs.

Poolbeg Pharma advances in POLB 001 and GLP-1 trials

Poolbeg Pharma Plc has released its audited results for 2024, highlighting significant advancements in cancer immunotherapy, including the promising POLB 001 therapy.

Poolbeg Pharma CEO participating in key conferences in March and April 2025

Poolbeg Pharma's CEO, Jeremy Skillington, will present at major industry conferences in March and April 2025, showcasing innovative therapies and advancements.

Poolbeg Pharma granted patent in Korea for POLB 001

Poolbeg Pharma (LON:POLB) secures a crucial patent for POLB 001 in South Korea, enhancing its portfolio for treating severe influenza and other conditions.

Poolbeg Pharma granted extension to PUSU Deadline

HOOKIPA Pharma and Poolbeg Pharma enter talks for a potential acquisition aimed at developing next-generation immunotherapies for critical medical needs.

Search

Search